In today's complex research landscape, studies rarely rely on a single data source. The most valuable insights often emerge from multi-modal research that combines biological specimens, electronic health record data, patient-reported outcomes, and direct participant feedback. Yet managing these diverse research streams has traditionally been a fragmented, resource-intensive process that introduces unnecessary complexity, delays, and costs.

When 23andMe recently filed for bankruptcy and California's Attorney General recommended customers delete their data, it highlighted a fundamental problem: health information is often treated as a company asset rather than personal property.

In an era of increasing digitization and remote capabilities in medical research, certain foundational elements remain irreplaceable. As Joined Bio announces its acquisition of BioSample Connect, we wanted to share our perspective on why clinical specimen collection continues to be a cornerstone of meaningful medical research, and how this strategic acquisition enhances our ability to serve the research community.

Every day, groundbreaking medical research stalls while scientists spend months searching for the right patients. Despite advances in medical technology, patient recruitment remains stubbornly anchored in the past—fragmented, inefficient, and frustratingly slow. But a revolution is underway, combining two powerful forces: artificial intelligence and real-time electronic medical records.

Throughout history, progress has often been measured by our ability to connect—connecting people to information, resources, and most importantly, to each other. When we look at the most transformative technological advances of the past few decades, a common thread emerges: the creation of digital platforms that eliminate inefficient intermediaries and create direct connections that were previously impossible or impractical.

The numbers are staggering. Every month a study is delayed costs sponsors between $600,000 to $8M in lost revenue potential.